Amgen (AMGN) Tops Q2 EPS by 26c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
August 4, 2022 4:01 PM EDTTHOUSAND OAKS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2022. Key results include:
Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, resulting from 3% growth in global product sales partially offset by lower Other Revenue from our COVID-19 manufacturing collaboration.Volumes grew double-digits for a number of products including Repatha® (evolocumab), Prolia® (denosumab), LUMAKRAS®/LUMYKRAS (sotorasib) and EVENITY® (romosozumab-aqqg).GAAP earnings per... More